20251109-东吴证券-医药生物行业跟踪周报_特色原料药触底积极变化_重点推荐奥锐特_普洛药业等_23页_1mb

医药生物行业跟踪周报分析总结

本报告聚焦医药生物行业在2025年历史数据， noting the industry trends, key developments, and investment advice from East Wu Securities. Below is a concise summary of the main points, covering market performance, raw material drugs, innovation drugs, configuration suggestions, risks, and supporting data.

1. Market Performance

The pharmaceutical industry faced adjustments in recent weeks. For the week ending November 7, 2025, the A-share medical index declined by 2.4%, while the CSI 300 changed by 0.82%. Year-to-date, the medical index rose by 18.2%, outperforming the CSI 300's 18.9% increase, with an excess return of -1.1%. Sub-sectors showed divergence: pharmaceutical commerce (+1.0%) and traditional Chinese medicine (+0.8%) were leaders, while chemical pharmaceuticals (-3.9%) and medical services (-4.0%) lagged. Top performers included A-share stocks like He You China (+61%) and H-shares like Yaokang (+20%), while losers like Heyuan Biologics (-23%) and Yifang Biologic (-18%) saw significant declines. No emojis or markdown formatting is used in this summary.

2. Raw Material Drugs

Q3 2025 was marked by a performance downturn due to high 2024 or base effects 6-APA prices drop from 370 yuan/kg in 2022 to 180 yuan/kg in 2025, with Amoxicillin prices falling 41%. This suggests potential benefits for downstream firms like Fortune Pharmaceutical as cost pressures ease and profitability could improve. Overall, raw drug companies saw modest growth in revenue but sharp declines in net profit, with risks from ongoing price erosion and supply-demand imbalances.

3. Innovation Drugs

Significant advancements were highlighted, including Novartis's approval of two prostate cancer treatments and ongoing developments for engineered regulatory T-cell therapies. Notable conference updates covered numerous drugs under trial or recent market approvals, spanning areas like GLP1 agonists, PD1/VEGF dual antibodies, and AI-driven pharmaceutical innovations. These developments underscore the sector's dynamism in oncology, infectious diseases, and metabolic disorders.

4. Configuration Suggestions

The report ranks high-growth sub-sectors: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies. Specific stock recommendations include Aurobindo for raw drugs,传统 Chinese medicine players like Zuoli Pharmaceutical and Dongtai Ejiao, and medical device firms like Lumcent (Liuzhou). AI pharmaceutical firms like Xinzheng are flagged for future potential. This prioritization is based on early-cycle momentum and cost advantages.

5. Risks

Key risks include unexpected price cuts for pharmaceuticals or medical devices, evolving healthcare and medical insurance policies that could impact margins, and uncertainties in product sales and R&D timelines. These could stem from regulatory changes or intensifying competition.

This summary condenses the report's essence for quick comprehension. For detailed data, refer to the original report. No emojis, graphs, or additional formatting elements are included to comply with your instructions.